Mineralys Therapeutics, Inc. 10-Q

Item 5. Other Information Not Applicable. Item 6. Exhibits Incorporated by Reference Exhibit Number Exhibit Description Form Date Number Filed Herewith 3.1 Amended and Restated Certificate of Incorporation 8-K 2/14/23 3.1 3.2 Amended and Restated Bylaws 8-K 2/14/23 3.2 4.1 Specimen stock certificate evidencing the shares of common stock S-1/A 2/2/23 4.1 4.2 Amended and Restated Investors’ Rights Agreement, dated June 1, 2022, by and among the Registrant and certain of its stockholders S-1/A 2/2/23 4.2 10.1# Mineralys Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan and form of stock option agreement and form of restricted stock agreement thereunder S-1/A 2/2/23 10.1 10.2# Mineralys Therapeutics, Inc. 2023 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder S-1/A 2/2/23 10.2 10.3# Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan S-1/A 2/2/23 10.3 10.4# Non-Employee Director Compensation Policy S-1/A 2/2/23 10.4 10.5#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between Jon Congleton and the Registrant S-1/A 2/2/23 10.5 10.6#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between David Rodman, M.D. and the Registrant S-1/A 2/2/23 10.6 10.7#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between Adam Levy and the Registrant S-1/A 2/2/23 10.7 10.8# Form of Indemnification Agreement for Directors and Officers S-1 1/18/23 10.8 31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 32.1* Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 x 32.2* Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 x 101.INS XBRL Instance Document x 101.SCH XBRL Taxonomy Extension Schema Document x 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document x 27 Table of Contents 101.DEF XBRL Taxonomy Extension Definition Linkbase Document x 101.LAB XBRL Taxonomy Extension Label Linkbase Document x 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document x 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) x __________________ # Indicates management contract or compensatory plan. † Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential. * This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. 28 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MINERALYS THERAPEUTICS, INC. Date: May 15, 2023 By: /s/ Jon Congleton Jon Congleton Chief Executive Officer (Principal Executive Officer) Date: May 15, 2023 By: /s/ Adam Levy Adam Levy Chief Financial Officer, Chief Business Officer, and Secretary (Principal Financial Officer; Principal Accounting Officer) 29